Funtleyder Leslie D.

SEC source: 0001193125-26-036140 · ownership.xml · derivative · entry 9

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 40,502 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

SEC source: 0001193125-26-036140 · ownership.xml · derivative · entry 8

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 150,000 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

SEC source: 0001193125-26-036140 · ownership.xml · derivative · entry 7

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,500 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

SEC source: 0001193125-26-036140 · ownership.xml · derivative · entry 6

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,500 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

SEC source: 0001193125-26-036140 · ownership.xml · derivative · entry 5

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,230 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

SEC source: 0001193125-26-036140 · ownership.xml · derivative · entry 4

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,460 shares

Expires not disclosed

F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.

SEC source: 0001193125-26-036140 · ownership.xml · nonDerivative · entry 3

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F2 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").

F4 · kind: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.

F4 · price: Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.

SEC source: 0001193125-26-036140 · ownership.xml · nonDerivative · entry 2

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 152,959

F2 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").

F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.

F2 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").

F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.

SEC source: 0001193125-26-001156 · ownership.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,340,459

F1 · shares: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan"). Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in equal monthly installments over the twenty-four month period immediately following January 1, 2026, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001193125-26-036140 · ownership.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,527,959

F1 · kind: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in full upon the earlier of (i) the consummation of a Change in Control (as defined in the Plan) or (ii) June 19, 2026, in each case, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001437749-25-038446 · rdgdoc.xml · derivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock, par value $0.0001 per share · 8,200 shares

Expires 2035-12-17

F1 · derivative.exercise_date: This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock, par value $0.0001 per share ("Common Stock"), subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.

SEC source: 0001193125-25-227148 · ownership.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,190,459

F1 · shares: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan"). Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in equal monthly installments over the twenty-four month period immediately following October 1, 2025, subject to the Reporting Person continuing to provide services through each such date.

F2 · balance_after: The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the understatement of the total holdings.

SEC source: 0000950170-25-093555 · ownership.xml · nonDerivative · entry 2

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 937,121

F3 · shares: Consists of compensatory RSUs granted under the Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in equal monthly installments over the twenty-four month period immediately following July 1, 2025, subject to the Reporting Person continuing to provide services through each such date.

F2 · balance_after: The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the overstatement of the total holdings.

SEC source: 0000950170-25-093555 · ownership.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 787,121

F1 · shares: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan"). Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. The compensatory RSUs shall vest in equal monthly installments over the twenty-four month period immediately following April 1, 2025, subject to the Reporting Person continuing to provide services through each such date.

F2 · balance_after: The total holdings have been adjusted to correct an administrative error in prior Form 4s that resulted in the overstatement of the total holdings.

SEC source: 0000950170-25-045613 · ownership.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 740,459

F1 · shares: Consists of compensatory Restricted Stock Units ("RSUs") granted under the Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory RSU represents a contingent right to receive one share of the Issuer's common stock. One fourth (1/4th) of the compensatory RSUs shall vest on March 24, 2026, and one thirty-sixth (1/36th) of the remaining shares subject to the compensatory RSUs shall vest each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0000950170-25-035041 · ownership.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 390,459

F1 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of compensatory Restricted Stock Units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

SEC source: 0000950170-25-016588 · ownership.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 404,961

F1 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of compensatory Restricted Stock Units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

SEC source: 0000950170-24-139239 · ownership.xml · derivative · entry 2

Funtleyder Leslie D. · CIK 0001775394 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 150,000

Underlying: Common Stock · 150,000 shares

Expires 2034-12-19

F2 · shares: Consists of Options granted under the Plan in connection with the Reporting Person's service as interim Chief Executive Officer. The Options will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested Options will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan).

F2 · derivative.exercise_date: Consists of Options granted under the Plan in connection with the Reporting Person's service as interim Chief Executive Officer. The Options will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested Options will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan).

SEC source: 0000950170-24-139239 · ownership.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 427,911

F1 · shares: Consists of compensatory Restricted Stock Units ("RSUs") granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan (the "Plan") in connection with the Reporting Person's service as interim Chief Executive Officer. Each compensatory RSU represents a contingent right to receive one share of the issuer's common stock. The compensatory RSUs will vest in equal monthly installments over the 12-month period following the grant date, subject to the Reporting Person continuing to provide services through each such vesting date, provided that any outstanding and unvested RSUs will vest immediately upon the earlier to occur of (i) the approval by the United States Food and Drug Administration of the issuer's proposed new drug application relating to the treatment of Sorbitol Dehydrogenase or (ii) a Change in Control (as defined in the Plan).

SEC source: 0001437749-24-037370 · rdgdoc.xml · derivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock, par value $0.0001 per share · 8,200 shares

Expires 2034-12-09

F1 · derivative.exercise_date: This option award (the "Option") was made in accordance with the terms of the 2020 Equity Incentive Plan (the "2020 Plan") of Reviva Pharmaceuticals Holdings, Inc. (the "Company"). The Option will vest at the rate of one hundred percent (100%) of the shares of common stock ("Common Stock") subject thereto upon the one year anniversary of the date of grant, provided that the reporting person remains a director of the Company through such vesting date. The exercise price is based on the closing price of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.

SEC source: 0000950170-24-100222 · ownership.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,911

F1 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of compensatory Restricted Stock Units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

SEC source: 0000950170-24-071325 · ownership.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 291,441

F1 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of compensatory Restricted Stock Units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

SEC source: 0001096906-24-000491 · form4.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 308,421

F1 · shares: The sale reported on this Form 4 represents shares sold by the reporting person to cover tax withholding obligations in connection with the vesting and settlement of compensatory Restricted Stock Units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the reporting person.

F2 · price: Weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $5.37 to $5.7855, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-23-056083 · doc4.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 337,148

F1 · shares: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan in connection with the Reporting Person's appointment as Chief Financial Officer. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. The compensatory Restricted Stock Units shall vest in equal monthly installments over the two-year period following the date of grant, subject to the Reporting Person continuing to provide services through each such vesting date.

SEC source: 0001437749-23-031992 · rdgdoc.xml · derivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock, par value $0.0001 per share · 8,200 shares

Expires 2033-11-12

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.

SEC source: 0001209191-23-035596 · doc4.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,148

F1 · shares: Consists of compensatory Restricted Stock Units granted under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. Each compensatory Restricted Stock Unit represents a contingent right to receive one share of the issuer's common stock. One-fourth (1/4th) of the Restricted Stock Units shall vest on each of September 6, 2023, December 6, 2023, March 6, 2024 and the date which is the earlier of June 6, 2024 and the 2024 annual stockholder meeting, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001437749-22-027080 · rdgdoc.xml · derivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,900

Underlying: Common Stock, par value $0.0001 per share · 3,900 shares

Expires 2032-11-09

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.

SEC source: 0001209191-22-044459 · doc4.xml · derivative · entry 8

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,460

Underlying: Common Stock · 20,460 shares

Expires 2029-05-12

F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F3 · derivative.exercise_date: These Options are fully vested.

SEC source: 0001209191-22-044459 · doc4.xml · derivative · entry 7

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,460 shares

Expires 2029-05-12

F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F3 · derivative.exercise_date: These Options are fully vested.

SEC source: 0001209191-22-044459 · doc4.xml · derivative · entry 6

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,230

Underlying: Common Stock · 10,230 shares

Expires 2030-06-03

F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F3 · derivative.exercise_date: These Options are fully vested.

SEC source: 0001209191-22-044459 · doc4.xml · derivative · entry 5

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,230 shares

Expires 2030-06-03

F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F3 · derivative.exercise_date: These Options are fully vested.

SEC source: 0001209191-22-044459 · doc4.xml · derivative · entry 4

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,500

Underlying: Common Stock · 16,500 shares

Expires 2031-06-02

F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F3 · derivative.exercise_date: These Options are fully vested.

SEC source: 0001209191-22-044459 · doc4.xml · derivative · entry 3

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,500 shares

Expires 2031-06-02

F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F3 · derivative.exercise_date: These Options are fully vested.

SEC source: 0001209191-22-044459 · doc4.xml · derivative · entry 2

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,500

Underlying: Common Stock · 16,500 shares

Expires 2032-06-02

F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F2 · derivative.exercise_date: Reflects an initial grant of 16,500 Options granted on June 3, 2022 that vests as follows: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001209191-22-044459 · doc4.xml · derivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 16,500 shares

Expires 2032-06-02

F1 · kind: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F1 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 2, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these Options.

F2 · derivative.exercise_date: Reflects an initial grant of 16,500 Options granted on June 3, 2022 that vests as follows: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001209191-22-034928 · doc4.xml · derivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,500

Underlying: Common Stock · 16,500 shares

Expires 2032-06-02

F1 · derivative.exercise_date: Consists of Options granted to directors under Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan. One-twelfth (1/12th) of the shares subject to the Option shall vest on July 2, 2022 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001437749-21-028318 · rdgdoc.xml · derivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,300

Underlying: Common Stock, par value $0.0001 per share · 5,300 shares

Expires 2031-12-07

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of one hundred percent (100%) of the shares subject thereto upon the one year anniversary of the date of grant, provided that Awardee remains a director of the Company through such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.

SEC source: 0001437749-21-014948 · rdgdoc.xml · derivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,000

Underlying: Common Stock, par value $0.0001 per share · 4,000 shares

Expires 2031-06-14

F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's 2020 Equity Incentive Plan (the "2020 Plan"). The Option will vest at the rate of thirty-three percent (33%) of the shares subject thereto upon the one year anniversary of December 14, 2020, and as to an additional thirty-three percent (33%) of the shares subject to the Option on each successive one year anniversary thereafter, provided that Awardee remains a director of the Company through each such vesting date. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2020 Plan.

SEC source: 0001209191-21-038424 · doc4.xml · derivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,500

Underlying: Common Stock · 16,500 shares

Expires 2031-06-02

F1 · derivative.exercise_date: One-twelfth (1/12th) of the shares subject to the Option shall vest on July 3, 2021 and each month thereafter, subject to the Reporting Person continuing to provide services through each such date.

SEC source: 0001209191-20-053946 · doc4.xml · nonDerivative · entry 4

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,148

F2 · shares: Sales made pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.6500 to $20.5600 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-053946 · doc4.xml · derivative · entry 5

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,502

Underlying: Common Stock · 30,000 shares

Expires 2029-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F6 · derivative.exercise_date: These options became fully vested on May 28, 2019.

F1 · derivative.underlying_shares: Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-20-053946 · doc4.xml · nonDerivative · entry 3

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,124

F2 · shares: Sales made pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $20.5100 to $21.1000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-053946 · doc4.xml · nonDerivative · entry 2

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,477

F2 · shares: Sales made pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $19.5100 to $20.5000 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-053946 · doc4.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,148

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-20-048318 · doc4.xml · nonDerivative · entry 3

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,148

F2 · shares: Sales made pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F4 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $23.9700 to $24.4100 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-048318 · doc4.xml · nonDerivative · entry 2

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,609

F2 · shares: Sales made pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $22.9400 to $23.8600 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

SEC source: 0001209191-20-048318 · doc4.xml · derivative · entry 4

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,502

Underlying: Common Stock · 20,000 shares

Expires 2029-03-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F5 · derivative.exercise_date: These options became fully vested on May 28, 2019.

SEC source: 0001209191-20-048318 · doc4.xml · nonDerivative · entry 1

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,148

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Compensatory options granted under Applied Therapeutics, Inc.'s 2016 Equity Incentive Plan, exercised pursuant to the reporting person's written trading plan, providing for the sale of shares underlying compensatory options in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 11

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,148

SEC source: 0001209191-20-039034 · doc4.xml · nonDerivative · entry 10

Funtleyder Leslie D. · CIK 0001775394 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,248

F10 · price: Weighted average price. These shares were sold in multiple transactions at prices ranging from $37.0000 to $37.9400 inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.